PURPOSE: We investigated the prognostic value of total metabolic tumour volume (TMTV) in diffuse large B-cell lymphoma (DLBCL). METHODS: TMTV was measured in 114 patients with newly diagnosed DLBCL who underwent (18)F-FDG PET/CT at baseline before immunochemotherapy. TMTV was computed by summing the volumes of all lymphomatous lesions after applying the local SUVmax threshold of 41% using semiautomatic software. Prognostic value was assessed by Kaplan-Meier estimates of progression-free survival (PFS) and overall survival (OS). RESULTS: Median follow-up was 39 months. Average pretherapy TMTV was 509 ± 568 cm(3). The 3-year estimates of PFS were 77 % in the low metabolic burden group (TMTV ≤550 cm(3)) and 60% in the high metabolic burden group (TMTV >550 cm(3), p = 0.04), and prediction of OS was even better (87% vs. 60%, p = 0.0003). Cox regression showed independence of TMTV for OS prediction (p = 0.002) compared with other pretherapy indices of tumour burden, such as tumour bulk and the International Prognostic Index. CONCLUSION: Pretherapy TMTV is an independent predictor of outcome in patients with DLBCL.
PURPOSE: We investigated the prognostic value of total metabolic tumour volume (TMTV) in diffuse large B-cell lymphoma (DLBCL). METHODS:TMTV was measured in 114 patients with newly diagnosed DLBCL who underwent (18)F-FDG PET/CT at baseline before immunochemotherapy. TMTV was computed by summing the volumes of all lymphomatous lesions after applying the local SUVmax threshold of 41% using semiautomatic software. Prognostic value was assessed by Kaplan-Meier estimates of progression-free survival (PFS) and overall survival (OS). RESULTS: Median follow-up was 39 months. Average pretherapy TMTV was 509 ± 568 cm(3). The 3-year estimates of PFS were 77 % in the low metabolic burden group (TMTV ≤550 cm(3)) and 60% in the high metabolic burden group (TMTV >550 cm(3), p = 0.04), and prediction of OS was even better (87% vs. 60%, p = 0.0003). Cox regression showed independence of TMTV for OS prediction (p = 0.002) compared with other pretherapy indices of tumour burden, such as tumour bulk and the International Prognostic Index. CONCLUSION: Pretherapy TMTV is an independent predictor of outcome in patients with DLBCL.
Authors: Laurie H Sehn; David W Scott; Mukesh Chhanabhai; Brian Berry; Anna Ruskova; Leanne Berkahn; Joseph M Connors; Randy D Gascoyne Journal: J Clin Oncol Date: 2011-03-07 Impact factor: 44.544
Authors: A Bari; L Marcheselli; S Sacchi; R Marcheselli; S Pozzi; P Ferri; E Balleari; P Musto; S Neri; M A Aloe Spiriti; M C Cox Journal: Ann Oncol Date: 2009-11-17 Impact factor: 32.976
Authors: Michael Pfreundschuh; Anthony D Ho; Eva Cavallin-Stahl; Max Wolf; Ruth Pettengell; Ingrid Vasova; Andrew Belch; Jan Walewski; Pier-Luigi Zinzani; Walter Mingrone; Stein Kvaloy; Ofer Shpilberg; Ulrich Jaeger; Mads Hansen; Claudia Corrado; Adriana Scheliga; Markus Loeffler; Evelyn Kuhnt Journal: Lancet Oncol Date: 2008-04-08 Impact factor: 41.316
Authors: L S Freudenberg; G Antoch; P Schütt; T Beyer; W Jentzen; S P Müller; R Görges; M R Nowrousian; A Bockisch; J F Debatin Journal: Eur J Nucl Med Mol Imaging Date: 2003-11-26 Impact factor: 9.236
Authors: Heiko Schöder; Andrew D Zelenetz; Paul Hamlin; Somali Gavane; Steven Horwitz; Matthew Matasar; Alison Moskowitz; Ariela Noy; Lia Palomba; Carol Portlock; David Straus; Ravinder Grewal; Jocelyn C Migliacci; Steven M Larson; Craig H Moskowitz Journal: J Nucl Med Date: 2015-12-30 Impact factor: 10.057
Authors: David M Kurtz; Michael R Green; Scott V Bratman; Florian Scherer; Chih Long Liu; Christian A Kunder; Kazuhiro Takahashi; Cynthia Glover; Colm Keane; Shingo Kihira; Brendan Visser; Jason Callahan; Katherine A Kong; Malek Faham; Karen S Corbelli; David Miklos; Ranjana H Advani; Ronald Levy; Rodney J Hicks; Mark Hertzberg; Robert S Ohgami; Maher K Gandhi; Maximilian Diehn; Ash A Alizadeh Journal: Blood Date: 2015-04-17 Impact factor: 22.113
Authors: Hajira Ilyas; N George Mikhaeel; Joel T Dunn; Fareen Rahman; Henrik Möller; Daniel Smith; Sally F Barrington Journal: Eur J Nucl Med Mol Imaging Date: 2018-11-01 Impact factor: 9.236
Authors: Qaid Ahmed Shagera; Gi Jeong Cheon; Youngil Koh; Min Young Yoo; Keon Wook Kang; Dong Soo Lee; E Edmund Kim; Sung-Soo Yoon; June-Key Chung Journal: Eur J Nucl Med Mol Imaging Date: 2019-04-02 Impact factor: 9.236